| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | -0.17 | 0.4 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.05 | 0.4 |